# Add Glucokinase Activator to Target A1c

> **NCT02405260** · PHASE2 · COMPLETED · sponsor: **vTv Therapeutics** · enrollment: 190 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** TTP399 400 mg
- **DRUG:** TTP399 800 mg
- **DRUG:** Sitagliptin 100 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02405260
- **Lead sponsor:** vTv Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2016-07
- **Final completion:** 2016-09
- **Target enrollment:** 190 (ACTUAL)
- **Last updated:** 2017-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02405260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02405260, "Add Glucokinase Activator to Target A1c". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02405260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*